Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study

por Lanteri-Minet, Michel, Goadsby, Peter J, Reuter, Uwe, Wen, Shihua, Hours-Zesiger, Peggy, Ferrari, Michel D, Klatt, Jan
Publicado 2021

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

por Reuter, Uwe, Ehrlich, Marc, Gendolla, Astrid, Heinze, Axel, Klatt, Jan, Wen, Shihua, Hours-Zesiger, Peggy, Nickisch, Jacqueline, Sieder, Christian, Hentschke, Christian, Maier-Peuschel, Monika
Publicado 2021

Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study

por Goadsby, Peter J., Reuter, Uwe, Lanteri-Minet, Michel, Paiva da Silva Lima, Gabriel, Hours-Zesiger, Peggy, Fernandes, Chrystel, Wen, Shihua, Tenenbaum, Nadia, Kataria, Aditi, Ferrari, Michel D., Klatt, Jan
Publicado 2021

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

por Wang, Shuu-Jiun, Roxas, Artemio A, Saravia, Bibiana, Kim, Byung-Kun, Chowdhury, Debashish, Riachi, Naji, Tai, Mei-Ling Sharon, Tanprawate, Surat, Ngoc, Tai Tran, Zhao, Yi Jing, Mikol, Daniel D, Pandhi, Shaloo, Wen, Shihua, Mondal, Subhayan, Tenenbaum, Nadia, Hours-Zesiger, Peggy
Publicado 2021